Navigation Links
InterMune Sells Danoprevir Rights to Roche for $175 Million
Date:10/6/2010

BRISBANE, Calif., Oct. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has sold worldwide development and commercialization rights to danoprevir (also known as RG7227 or ITMN-191) to Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd. for $175 million in cash.  In connection with this transaction, the collaboration agreement that InterMune and Roche entered into in October 2006 has been terminated.  In addition, the companies are actively exploring ways to continue their ongoing work together on other HCV research programs.  InterMune noted that as a result of this transaction, the company will make no further investment in danoprevir and that, including net proceeds from the transaction, it currently expects to have a cash balance of approximately $290 million at the end of 2010.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "After conducting a careful review of our strategy and financial position, we have decided to divest our rights to danoprevir to Roche.  This transaction provides a very substantial non-dilutive cash infusion that allows us to continue to independently and aggressively pursue the registration and commercialization of pirfenidone in the US and EU, and eliminates our obligation to make significant ongoing investments related to the further development and commercialization of danoprevir.  We are now in a very strong financial position that provides us with the resources and flexibility to maximize the value of pirfenidone, our largest and nearest-term value creation opportunity."

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EDT to discuss the transaction.  Interested investors and others may participate in the conference call by dialing 866-408-9480 (U.S.) or 706-643-9223 (international), con
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at 2010 Citi Health Care Conference
2. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
3. InterMune to Release First Quarter Financial Results on April 29
4. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
5. InterMune Announces Proposed Public Offering of Common Stock
6. InterMune to Release Third Quarter Financial Results on November 5
7. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
8. InterMune to Present at Canaccord Adams Conference
9. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
10. InterMune to Release Second Quarter Financial Results on August 6
11. InterMune to Present at Goldman Sachs Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... addition of Jain PharmaBiotech,s new report "Personalized ... their offering. , The aim ... match the right drug to the right patient ... appropriate treatment for a patient according to his/her ...
(Date:3/3/2015)... 2015  Johnson & Johnson Innovation LLC today announced ... (JLABS @SSF), a 30,000-square foot incubator located ... Francisco, Calif. The Johnson & Johnson Innovation, ... from across the healthcare spectrum including biotech, pharmaceutical, medical ... first resident startups have been selected, including the winners ...
(Date:3/3/2015)... , March 3, 2015  Synthetic Biologics, Inc. (NYSE ... and diseases, with a focus on protecting the microbiome, announced ... scheduled to present at the 27th Annual ROTH Conference being ... Laguna Niguel in Dana Point, CA. ... March 10, 2015 at 1:00 p.m. (Pacific Time). ...
(Date:3/3/2015)... March 03, 2015 GlobalStemCellsGroup.com ... faculty. Camacho Alcocer, a biomedical researcher and founding partner ... join GSCG’s team of biomedical professors who will teach ... , Criogenix SA de CV is a private company ... Institutions and Companies in Mexico (RENIECYT). , Camacho Alcocer ...
Breaking Biology Technology:Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5Synthetic Biologics to Present at the 27th Annual ROTH Conference 2Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 2Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 3
... , ... therapeutics company, announces that the first clinical center in the,US, ... the phase III clinical study of Alpharadin in men with,castration-resistant ... the skeleton. , The ALSYMPCA (ALpharadin ...
... Dec. 11 Gwathmey, Inc., a pre-clinical contract ... aureus, and cardiovascular disease announces a new CEO. ... Ph.D., has joined Gwathmey as Chief Executive Officer. ... with small businesses and the federal government. Prior ...
... ... announces the opening of a NEW 2nd North American facility in Marietta, OH. The facility ... the North American market, specifically in the area of New Product Introductions (NPI) for temperature-controlled ... Hatboro, PA ...
Cached Biology Technology:Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2
(Date:2/25/2015)... , Feb. 25, 2015  ABC Financial ... billing in the Health and Fitness Industry, today ... as to MYiCLUBonline.  The latest upgrade includes advances ... inclusion of cardless check-in via Identity One fingerprint ... first time through interactive displays at the International ...
(Date:2/19/2015)... , Feb .19, 2015 Research and ... the addition of the "Military Electro-Optical / ... Sensor Technology, by Platform - Forecast to 2020" ... The military electro-optical/infrared systems market is expected to ... CAGR of 7.71%. This report segments ...
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... , The President of the Deutsche Forschungsgemeinschaft (DFG, ... decision by the German Federal Parliament on the Stem ... grateful for the decision taken by Parliament. We are ... towards the critical debate of the issue. The ...
... the green off the potatoes. Any child would know ... idea. The reason behind this is that they contain ... the consumer. Each night, tropical fruit-eating bats ingest ... This may become particularly problematic for pregnant or lactating ...
... researchers from around the world will present the latest ... waves at the 2008 Conference on Lasers and Electro-Optics/Quantum ... at the San Jose McEnery Convention Center in San ... for those in the lasers and electro-optics community. It ...
Cached Biology News:Why fruit-eating bats eat dirt 2Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 2Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 3Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 4Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 5Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 6Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 7
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
C/EBPdelta Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Ubiquitin-like protein 4A (Ubiquitin-like protein GDX). [Source:Uniprot/SWISSPROT;Acc:P11441] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
Biology Products: